Objective: To present aspects of the evolution of lipoid pneumonia in children, based on clinical, radiological and bronchoalveolar lavage fluid findings, emphasizing the importance of bronchoalveolar lavage for the diagnosis and treatment.
Methods: We included 28 children, with a mean age of 20 months (range, 1-108 months), diagnosed with chronic pneumonia refractory to antimicrobial therapy, with TB or with a combination of the two. Most of the children had at least one risk factor for aspiration, and all of them had a history of mineral oil ingestion for intestinal constipation (23/28) or complicated ascaridiasis (5/28). Clinical evaluations, tomographic evaluations and analyses of bronchoalveolar lavage fluid were carried out at the beginning of treatment and throughout a follow-up period of 24 months.
Results: Tachypnea and cough were the most common symptoms. The most common radiological alterations were areas of consolidation (23/28), perihilar infiltrates (13/28) and hyperinflation (11/28). Chest CT scans showed areas of consolidation with air bronchogram (24/28), decreased attenuation in the areas of consolidation (16/28), ground-glass opacities (3/28) and crazy-paving pattern (1/28). In the analysis of the bronchoalveolar lavage fluid, Sudan staining revealed foamy macrophages, confirming the diagnosis of lipoid pneumonia. After treatment with multiple bronchoalveolar lavages (mean = 9.6), 20 children became asymptomatic, 18 of those presenting normal tomographic images.
Conclusions: A diagnosis of lipoid pneumonia should be considered in patients with chronic refractory pneumonia or TB, especially if there is a history of mineral oil ingestion. Bronchoscopy with multiple bronchoalveolar lavages was an efficient treatment for the clearance of mineral oil from the lung parenchyma and the prevention of fibrosis. This strategy contributed to reducing the morbidity of lipoid pneumonia, which remains a rare diagnosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s1806-37132009000900004 | DOI Listing |
Cell Mol Biol (Noisy-le-grand)
January 2025
Department of Medical Microbiology, Faculty of Science and Health, Koya University, Koya KOY45, Kurdistan Region-F.R., Iraq.
Klebsiella pneumoniae is a non-motile, encapsulated, environmental gram-negative bacterium. Once the bacteria have infiltrated the body, they can display substantial degrees of resistance to drugs and virulence. Extended Spectrum Beta-Lactamases (ESBLs) are most typically seen in K.
View Article and Find Full Text PDFRadiol Cardiothorac Imaging
February 2025
From the Department of Diagnostic and Interventional Radiology (D.B., M.H.P.) and Department of Pathology and Cytology (S.S.J.), University Hospital Center Zagreb, Kišpatićeva 12, 10 000 Zagreb, Croatia; Clinic for Lung Diseases Jordanovac, University Hospital Center Zagreb, Zagreb, Croatia (M.K.); and University of Zagreb School of Medicine, Zagreb, Croatia (M.K., S.S.J., M.H.P.).
J Clin Med
December 2024
Department of Pneumology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400332 Cluj-Napoca, Romania.
The mortality rate from community-acquired pneumonia (CAP) or coronavirus disease 19 (COVID-19) is high, especially in hospitalized patients. This study aimed to assess the disturbances of glucose and lipid metabolism with in-hospital complications and short-term outcomes for patients with pneumonia with different etiologies. This observational study comprised 398 patients divided as follows: 155 with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia, 129 participants with viral CAP, and 114 with bacterial pneumonia.
View Article and Find Full Text PDFmSphere
December 2024
Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, China.
is a prominent Gram-negative and encapsulated opportunistic pathogen that causes a multitude of infections such as severe respiratory and healthcare-associated infections. Despite the widespread anti-microbial resistance and the high mortality rate, currently, no clinically vaccine is approved for battling . To date, messenger RNA (mRNA) vaccine is one of the most advancing technologies and are extensively investigated for viral infection, while infrequently applied for prevention of bacterial infections.
View Article and Find Full Text PDFToxicol Appl Pharmacol
December 2024
Department of Pathology, Faculty of Veterinary Medicine, Cairo University, P.O. Box 12211, Giza, Egypt.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!